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IN VITRO SIMULATION OF CALCIFIC AORTIC VALVE DISEASE 
IN THREE-DIMENSIONAL BIOPRINTED MODELS 
PIN-JOU WU 
ABSTRACT 
Background: 
Calcific aortic valve disease (CAVD) is the most prevalent heart valve disease in the 
developed world, claiming almost 17,000 deaths annually in the United States. The lack 
of noninvasive therapeutics to slow or halt the disease warrants the need for further 
understanding of the pathobiological mechanisms of CAVD. A tri-laminar structure of 
aortic valve determines the biomechanical properties of its leaflets. Valvular endothelial 
cells (VECs) and interstitial cells (VICs) are responsible for valve structural integrity. 
Traditional two-dimensional culture conditions spontaneously activate the pathological 
differentiation of VICs making in vitro studies challenging. A monolayered three-
dimensional (3D) hydrogel platform was recently developed as a novel in vitro culture 
system to study the phenotypic changes of VICs leading to microcalcification (early 
stages of calcification). This system, however, did not fully recapitulate the 
microenvironment of native valve tissues because of the lack of individual layer 
representations and endothelial coverage. Bioprinting technology, which allows precise 
and integrated positioning of cells, matrix, and biomolecules, may provide an innovative 
approach toward building a more biologically relevant 3D culture platform. 
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Objective: 
This study aims to lay the groundwork for building a multilayered 3D-bioprinted culture 
platform to study CAVD by first validating the use of bioprinting in monolayered cell-
laden 3D hydrogel constructs. 
 
Methods: 
Human VICs were isolated from patients undergoing valve replacement surgeries at 
Brigham and Women’s Hospital (Boston, MA) according to Institutional Review Board 
(IRB) protocols. VICs were expanded in culture medium containing growth factors for up 
to 6 passages and then encapsulated in hydrogels using 3D bioprinting technology. After 
encapsulation, VIC-laden 3D constructs were cultured in either normal or osteogenic 
conditions for 21 days. Microcalcification, cell proliferation, and cell apoptosis were 
evaluated using fluorescent staining and confocal microscopy. Results were compared 
with results from VIC-laden hydrogels made manually. 
 
Results: 
An increase in microcalcification was observed throughout bioprinted VIC-laden 
hydrogel constructs cultured in osteogenic conditions for 21 days, whereas normal 
conditions developed negligible calcification signals. Cell proliferation and apoptosis 
were not significantly different between normal and osteogenic groups in bioprinted 
hydrogels. Cell-free hydrogels did not exhibit any microcalcification. Overall, bioprinted 
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hydrogels showed less nonspecific background staining than handmade hydrogels, thus 
providing a better means for quantitative assessments of 3D culture platforms. 
 
Conclusion:  
Based on bioprinting technology, an improved monolayered cell-laden hydrogel platform 
was successfully established as a first step toward building an in vitro multilayered 
disease model for studying the pathobiological mechanisms of CAVD. The results in this 
study were consistent with current literature that proposes calcification as a cell-
dependent, apoptotic-independent, and proliferation-independent pathway. 
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INTRODUCTION 
 
Calcific Aortic Valve Disease 
Calcific aortic valve disease (CAVD) is a progressive disorder with a disease 
continuum that ranges from mild valve fibrosis to severe valve calcification (Figure 1).1 
In the early stages of CAVD, most affected individuals have mild valve thickening with 
minimal hemodynamic disturbance, termed aortic valve sclerosis.2 Over a period of just 
2-7 years,3 some patients advance to late-stage calcification where large calcific masses 
impair leaflet motion and valve function, resulting in aortic valve stenosis—a narrowing 
of the aortic valve opening.4 This obstruction of left ventricular outflow leads to 
progressive left ventricular hypertrophy, and without intervention, heart failure and death 
ensue. For many years, aortic valve stenosis caused by CAVD has been the most 
prevalent heart valve disease, particularly in the elderly population of developed 
countries. In the United States alone, CAVD has claimed nearly 17,000 lives every year5 
and affected 1 in 4 adults older than 65 years of age.6 
 
Treatment 
Despite the poor prognosis and significant clinical need for an improved treatment 
strategy, there are currently no effective pharmacological therapies to slow or halt the 
progression of CAVD.7 Lipid-lowering therapy was once considered to be a potential 
therapy to reduce CAVD progression based on the similarities between identified lesions 
and atherosclerotic lesions. However, lipid-lowering therapy was shown to be ineffective 
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in a meta-analysis of randomized placebo-controlled clinical trials on 2344 patients with 
aortic valve stenosis.8 Currently, the only standard treatment for patients with severe 
aortic valve stenosis is to undergo an invasive and costly aortic valve replacement 
(AVR).9 These procedures are often delayed until gross calcium deposits severely impair 
the patient’s aortic valve function.10 Over 275,000 surgical AVRs are performed annually 
worldwide,11 and this number is projected to triple by 2050 given the rising global life 
expectancy.11 In 2002, as a surgical alternative, technology enabled the development of 
transcatheter AVR, a technique in which a bioprosthetic valve is inserted by means of a 
catheter and implanted within the diseased native aortic valve.12 However, given an 
increased risk for periprocedural complications, this option is currently only 
recommended for high-risk patients deemed inoperable.13 Nevertheless, more than 80,000 
transcatheter AVRs have been performed worldwide to date.14 These statistics emphasize 
the growing burden of CAVD and the necessity to pursue a better understanding of the 
disease process, which can potentially lead to noninvasive, drug-based treatments. 
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Figure 1. Three distinct stages of CAVD.1 The progression of CAVD is an 
inflammation-dependent mechanism and can be detected using molecular imaging: 
macrophages are labeled in green, and calcification is labeled in red. The current imaging 
window is restricted to the late-stage of the disease, highlighting the need to detect the 
disease at an earlier stage for therapeutic intervention. 
 
The Aortic Heart Valve 
To fully understand the impact of CAVD requires an appreciation of the aortic 
valve (AV) structure and how that correlates with its function. Situated at the junction 
between the left ventricle and the aorta, the AV controls unidirectional blood flow from 
the heart into the systemic circulation. During systolic contraction of the ventricles, the 
three thin, semilunar leaflets recoil toward the aortic wall and open the pathway for blood 
Initiation Propagation Late-­‐‑stage 
Initiation Propagation Late-­‐‑stage 
Inflammation 
Early	  detection 
	  for	  therapeutic	   
intervention 
Current	  imaging	  window 
Calcification 
Sclerosis Stenosis 
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flow. As the heart relaxes in diastole, the reverse pressure forces the leaflets to stretch 
and seal the orifice, preventing retrograde blood flow into the heart.15 
The proper functioning of the AV is accomplished by a complex tissue 
architecture consisting of specialized cell populations and heterogeneous extracellular 
matrix (ECM) (Figure 2). Each leaflet consists of three distinct layers: the ventricularis, 
the spongiosa, and the fibrosa. Proximal to the ventricle is the zona ventricularis, a layer 
rich in elastin fibers providing elasticity for the leaflet to extend and recoil. On the 
opposite side facing the aorta is the zona fibrosa. This layer is densely packed with 
collagen fibers which offer the tensile strength required to prevent leaflet prolapse under 
diastolic stress. In between these two layers is the zona spongiosa, which predominantly 
consists of glycosaminoglycans (GAGs) and proteoglycans. This lubricating layer 
reduces friction between the zona ventricularis and the zona fibrosa.15 
 Two resident cellular populations in the AV maintain the tissue homeostasis and 
its health. The valvular endothelial cells (VECs) sheathe the blood-contacting surfaces, 
creating a barrier between the internal tissue components and the blood. The valvular 
interstitial cells (VICs) are the more abundant resident cells that populate all three layers 
of the leaflets. The main functions of VICs include synthesizing, repairing, and degrading 
the ECM. VICs are known to be a heterogeneous cell population as multiple VIC 
phenotypes have been identified in AV leaflets.16 
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Figure 2. Schematic representation of the AV microarchitecture.17 The AV leaflets 
have three inner layers. Each inner layer consists of specific cellular and ECM 
components that maintain the mechanical and biological functions of the valve. The 
leaflets are coated with endothelial cells on both the aortic and the ventricular blood-
contacting surfaces. 
 
Pathobiology  
In the past, CAVD was conventionally viewed as a passive, degenerative disease 
given its association with aging and the time-dependent mechanical wear-and-tear of the 
tissue. However, the results of many studies have shifted the current view on CAVD to 
an active, cell-driven disease (Figure 3).17 In healthy native valves, VICs remain in a 
quiescent state with characteristics like fibroblasts. These quiescent VICs can 
differentiate into an activated, myofibroblast-like phenotype (aVIC) given exogenous 
stimulations—a transition hallmarked by increased expression of contractile and 
collagen-secreting proteins such as alpha-smooth muscle actin (a-SMA).18,19 As aVICs, 
these pro-fibrotic cells participate in tissue repairing and remodeling. However, 
continuous activation of VICs results in the persistent synthesis and deposition of ECM 
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attributed to valve fibrosis.18 Moreover, aVICs can further differentiate into osteoblast-
like cells (oVICs) characterized by the presence of osteoblast-related proteins, including 
osteocalcin, osteonectin, and osteogenic transcription factors such as runt-related 
transcription factor 2 (Runx2).20 These pro-calcific cells are thought to be responsible for 
the deposition of calcium phosphate minerals within the ECM and ultimately the 
formation of calcific nodules as seen in late stages of CAVD.20,21 In distinct 
subpopulations of VICs, the expression of progenitor cell markers, such as ATP-binding 
cassette sub-family G member 2 (ABCG2), has been identified as a possible contributor 
to the development of osteogenic VICs during valve pathology.22 Others have also shown 
that the level of circulating osteogenic progenitor cells are significantly higher in CAVD 
patients compared with control patients.23  These studies suggest that VICs are a more 
heterogeneous cell population than previously thought. The extent of VIC heterogeneity 
(including progenitor cells) and the contribution of VIC subpopulations to the 
development of CAVD require further investigation. 
  The disease development of CAVD is multifaceted as it involves multiple, 
interacting pathogenic processes and events which may trigger the pathological 
differentiation of VICs. For instance, triggers such as mechanical stress, oxidative stress, 
inflammatory cytokines, growth factors, and subendothelial deposits of oxidized low-
density lipoprotein (LDL) have been described as sources of endothelial dysfunction 
leading to VEC/VIC activation.24–28 In addition, VECs have also been associated with the 
promotion of pathological remodeling in CAVD based on their capacity to differentiate 
into endothelial-derived VICs (eVICs) through an endothelial-to-mesenchymal transition 
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(EndMT), and these eVICs may further differentiate into osteoblastic cells.29 It has been 
demonstrated that such an EndMT process may be accelerated by the disruption of VIC-
VEC communication.30 
 
 
Figure 3. Schematic illustration of the progression of VIC differentiation in CAVD.31 
Upon exogenous stimulation, qVICs differentiate into myofibroblast-like aVICs, 
characterized by increased a-SMA expression. In healthy valves, aVICs can return to 
qVICs. However, in diseased valves, aVICs may further differentiate into osteoblast-like 
oVICs, characterized by increased Runx2 expression and decreased a-SMA expression. 
 
Development of 3D CAVD Models  
Despite various pathophysiological cues linking the activation of VICs to CAVD, 
the current understanding has mainly been based on experimental in vivo animal models 
or in vitro cell studies. Although in vivo animal models have the capacity to simulate the 
complexity of organ systems in a natural physiological environment similar to humans, 
these models often make it impossible to dissect individual mechanisms contributing to 
the specific disease process. In addition, many in vivo experiments required dietary 
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and/or genetic manipulations to induce diseases that are not currently considered as a 
main etiology of CAVD.7 As for in vitro cell studies, the unnatural two-dimensional (2D) 
cell culturing environment has been shown to spontaneously promote myofibroblast VIC 
activation.32 Hence, the lack of adequate in vitro CAVD models—ones that closely 
resemble the in vivo microenvironment native to the AV—has hindered further CAVD 
research, especially during the early stages of the disease. 
Advances in biomaterials, particularly in the use of hydrogels mimicking the 
tissue microenvironment, have been broadly utilized as a means for tissue engineering. 
The nature of the high water content possessed by hydrogels provides a sufficiently 
hydrophilic environment for cell survival and growth similar to that in the native ECM.33 
Hydrogel-based scaffolds also provide structural support and regulate cellular function 
and signaling.34 Over time, the embedded cells deposit new ECM in place of the hydrogel, 
forming new tissue. In an effort to establish a more tissue-like environment to investigate 
VIC behaviors, emerging studies have employed three-dimensional (3D) cell culture 
platforms using various types of hydrogels. For instance, hyaluronan hydrogels35 and 
synthetic PEG-based hydrogels36,37 have been used to engineer heart valve tissue scaffolds. 
Other studies have utilized natural ECM polymers such as collagen and fibrin, but these 
naturally derived materials were susceptible to degradation and compaction despite 
permitting high cell viability.38 
Recently, Hjortnaes et al. studied VIC phenotypic changes using a tunable in vitro 
3D hybrid hydrogel platform at our laboratory.32 Two hydrogels made from modified, 
naturally derived polymers were combined—methacrylated gelatin (GelMA) and 
	  9 
methacrylated hyaluronic acid (HAMA). These hydrogels had been successfully used 
individually as photocrosslinkable materials for VIC-laden hydrogels.39,40 However, 
GelMA-based hydrogels formed mechanically weak materials that were quick to 
degrade,41 and HAMA-based hydrogels were slow to degrade but were compromised by 
limited cell adhesiveness.40 Because hyaluronic acid is an important component of the 
ECM, the addition of HAMA to GelMA was thought to increase the structural integrity 
required to withstand longer experimental times, which GelMA alone could not provide.41 
Therefore, by using a concentration of 5% (v/v) GelMA and 1% (v/v) HAMA, Hjortnaes 
et al. found that this combination of hydrogels provided the appropriate stiffness (~20 
kPa) similar to the native valve tissue environment (~21 kPa) for maintaining the 
encapsulated porcine VICs in their quiescent state.31,32 Moreover, when stimulated with 
transforming growth factor beta 1 (TGF-b1), the quiescent VICs differentiated into 
myofibroblast-like phenotype30 and further to osteoblast-like phenotype when cultured in 
osteogenic conditions.31 The formation and growth of microcalcification, recapitulating 
the early stages of CAVD, were also observed, thus appropriately modeling the cellular 
processes associated with CAVD.42 
 
3D Bioprinting of Biological Structures  
3D bioprinting is an emerging fabrication technology that has become 
increasingly used in many biomedical applications, particularly in tissue engineering. In 
short, 3D bioprinting is a process of additive manufacturing—depositing cell-laden 
biomaterials layer by layer in micron-scale resolution and fusing layers together to make 
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a 3D biological structure.43 Contrary to the conventional top-down tissue engineering 
approach, in which cell-free scaffolds are first printed and subsequently seeded with cells, 
bioprinting is compatible with depositing living cells that have already been combined 
with biomaterials.44 This process allows the positioning of cells, matrix, and biomolecules 
to be more precise and integrated, which are crucial factors affecting cell survival, 
proliferation, and differentiation.45 Moreover, bioprinting offers the possibility of 
building heterogeneous structures that the traditional top-down tissue engineering 
approach cannot offer. This capability becomes very useful when the tissue, such as the 
AV leaflets, is composed of multiple layers with distinct cellular and biomechanical 
properties. With these advantages, bioprinting significantly improves the controllability 
of tissue fabrication, hence more closely mimicking the structure of the native valve.44 
Although our previously established 3D hybrid hydrogel culture platform was 
successful in allowing us to study the phenotypic changes of VICs leading to 
microcalcification formation, the system was not ideal as it did not examine VICs from a 
human source. Second, the system did not fully represent the three distinct layers that 
contribute independently to the calcification process within the valve leaflets. And third, 
the system did not include the endothelial cell layers covering the leaflets. Thus, our 
interest is to apply bioprinting technology to eventually fabricate a 3D disease model that 
will incorporate all distinct cellular and matrix components recapitulating the native 
human valve, including the potential to co-culture endothelial cells on the surfaces to 
study VIC-VEC communication and paracrine signaling. Furthermore, an automated 
system will allow us to reproduce our models more efficiently, with higher precision and 
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less construct-to-construct variability. This improved reproducibility will be 
tremendously beneficial as the 3D-bioprinted model recapitulating CAVD and closely 
mimicking the in vivo valve environment will eventually be used as a high-throughput 
screening platform for drug discovery.46  
 Therefore, in this study we hope to lay the groundwork for building a 
multilayered 3D-bioprinted disease model by first validating the use of bioprinting in our 
monolayered 3D hybrid hydrogel culture platform. By incorporating the latest 3D 
bioprinting technology, we aim to develop a second-generation in vitro 3D hydrogel 
platform that will serve as a physiologically relevant system to study microcalcification 
formation in modeling the initial changes in CAVD. 
 
Specific Aims 
As a first step in creating a disease model that adequately simulates the in vivo 
microenvironment in the native valve for studying the pathobiological mechanisms of 
CAVD, this study will address the following specific aims: 
(1)  Construct a novel in vitro monolayered VIC-laden 3D hybrid hydrogel platform 
using the latest 3D bioprinting technology. 
(2)  Introduce pathological cues to stimulate human VIC microcalcification in the 3D-
bioprinted hydrogel platform. 
(3)  Assess the differences in cell behaviors and calcification in the new bioprinted 3D 
platform compared with the previously established handmade 3D platform. 
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METHODS 
 
Human Aortic Valvular Interstitial Cell Isolation and Culture 
AV leaflets were obtained from patients with aortic valve stenosis and 
calcification undergoing surgical valve replacement at Brigham and Women’s Hospital 
(Boston, MA) according to Institutional Review Board (IRB) protocols. After dissection, 
valve leaflets were stored in Dulbecco’s Modified Eagle’s Medium (DMEM) (Lonza, 
Walkersville, MD, USA) on ice for a maximum of 3 hours prior to VIC isolation. The 
leaflets were rinsed in cold phosphate-buffered saline (PBS) to remove residual blood. 
Under sterile conditions, the leaflets were minced into 2-mm pieces, rinsed twice with 
PBS to remove gross calcific nodules, and incubated with 7 mL of sterile-filtered 0.1% 
(w/v) collagenase (C5894; Sigma-Aldrich Corporation) in DMEM for 1 hour at 37 °C 
with gentle rotation. Then the supernatant containing a mixture of VECs and VICs was 
aspirated. Tissue pieces were washed with DMEM and digested again with 7 mL of 
sterile-filtered 0.1% collagenase in DMEM for 3 more hours at 37 °C with gentle rotation. 
The supernatant containing VICs was collected over a 40 µm cell strainer to filter out the 
remaining tissue pieces and calcific nodules. An equivalent amount of growth medium, 
consisting of DMEM supplemented with 10% (v/v) fetal calf serum and 1% (v/v) 
penicillin-streptomycin, was added to dilute the supernatant and to rinse off released 
VICs from the remaining tissue pieces. Cells were centrifuged at 1100 rpm, resuspended, 
and cultured in growth medium at 37 °C and 5% CO2. Primary cultures were washed with 
growth medium to remove unattached cells two days post-isolation. Medium was 
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replenished three times a week, and cells were subcultured at 80% confluency. Cells from 
three different donors between passages 3 and 6 were used in this study. 
 
Synthesis of Polymer Precursors 
The synthesis of methacrylated gelatin (GelMA)47 and methacrylated hyaluronic 
acid (HAMA)48 pre-polymers has been reported previously. Both materials used in this 
study were synthesized in the Robert Langer Lab at Massachusetts Institute of 
Technology (MIT), Cambridge, MA. Briefly, to make 10% (w/v) gelatin solution, 
powdered gelatin from porcine skin (Sigma-Aldrich Corporation) was dissolved in PBS 
at 60 °C and stirred for about 20 minutes until fully dissolved. A solution of 8% (v/v) 
methacrylic anhydride was added to the mixture dropwise and continuously stirred for 3 
hours at 50 °C. The solution was diluted and dialyzed against deionized water in a 12-14 
kDa cutoff membrane at 40 °C for one week. The resulting solution was frozen at -80 °C 
and then lyophilized for one week to obtain a solid product, which was stored at -80 °C 
until further use. Proton nuclear magnetic resonance (1H NMR) analysis was used to 
determine a degree of approximately 80% methacrylation. 
For synthesis of HAMA pre-polymer, 1% (v/v) methacrylic anhydride was added 
to 1% (w/v) hyaluronic acid in distilled water. A volume of 5 M sodium hydroxide was 
used to adjust the pH of the mixture to between 8 and 10. The reaction was performed on 
ice for 24 hours while the pH was maintained. Afterward, the solution was dialyzed 
against deionized water in a 12-14 kDa cutoff membrane for 3 days at 4 °C. The resulting 
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solution was frozen at -80 °C and then lyophilized for 3 days. The solid product was 
stored at -80 °C until further use. A degree of about 20% methacrylation was measured 
by 1H NMR analysis. 
 
Hybrid Hydrogel Preparation with VIC Encapsulation 
For the preparation of GelMA pre-polymer solution, lyophilized GelMA pre-
polymer was dissolved in PBS at a final concentration of 10% (w/v) and placed in a 
sonicating bath at 37 °C until completely dissolved. This solution was stored at 4 °C as 
solid state and heated to liquid state at 37 °C prior to each experimental use.  HAMA pre-
polymer solution was prepared by dissolving lyophilized HAMA pre-polymer in warm 
PBS at a final concentration of 3% (w/v). The pH was adjusted to 7.5 using 5 M sodium 
hydroxide. This solution was stored at 4 °C and heated to 37 °C prior to each 
experimental use. Both GelMA and HAMA pre-polymer solutions were sterile-filtered 
using a 0.2 µm syringe filter. 
For the fabrication of hybrid hydrogels, a final concentration of 5% (v/v) GelMA 
and 1% (v/v) HAMA in growth media were mixed with a 0.5% (w/v) photoinitiator (PI) 
solution at a final concentration of 0.3% (v/v).31,49 The PI solution was produced by 
dissolving 5 mg of lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) in 1 mL of 
PBS at 60 °C. The pre-polymer mixture temporarily formed a gel-like consistency as 
temperature dropped but reversed to a liquid consistency on heating. Upon exposure to 
ultraviolet (UV) light, the mixture formed a hydrogel permanently. Human VICs were 
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resuspended in the pre-polymer mixture at a density of 10 million cells/mL. The resulting 
VIC-laden pre-polymer mixture was carefully transferred to a 10 mL Luer-Lok syringe 
under sterile conditions and protected from light. The mixture was subsequently used in 
either manual or bioprinted hydrogel fabrication. In the fabrication of cell-free hydrogels, 
the addition of VICs was omitted. 
 
Manual Fabrication of Human VIC-Laden 3D Hydrogels 
Fabrication of the handmade VIC-laden 3D hydrogel prototype was adopted from 
the methods reported in previous studies.31,32 In the present study, human VICs were used 
instead of porcine VICs. Briefly, 50 µL of VIC-laden GelMA/HAMA mixture was 
pipetted dropwise to a sterile petri dish between two spacers with a height of 450 µm 
(Figure 4; step 2). After the mixture was covered with a sterile glass slide, the construct 
was photocrosslinked for 30 seconds of exposure to 2.5 mW/cm2 UV light (Figure 4; step 
3). The VIC-laden hydrogel discs were then transferred to and cultured in 24-well plates 
containing either growth medium or osteogenic medium (described in the Calcification 
Promotion section) for 21 days. Medium was replenished 3 times a week. Two VIC-laden 
hydrogels were prepared for each condition. 
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Figure 4. Schematic representation of manual fabrication of VIC-laden hydrogels.32 
(1) Human VICs are resuspended in hybrid hydrogel pre-polymer mixture with PI. (2) A 
volume of 50 µL of VIC-laden mixture is pipetted dropwise in between two spacers and 
covered with a sterile glass slide. (3) The construct is exposed to UV light for 30 seconds 
at intensity of 2.5 mW/cm2. (4) VIC-laden hydrogel is formed. 
 
Engineering 3D-Bioprinted Hydrogel Constructs 
The 3D hydrogel constructs were designed using Tinkercad, online 3D computer-
aided design (CAD) software (AutoDesk, Inc., San Rafael, CA, USA). The desired 
dimensions of the VIC-laden hydrogels were 8.0 mm in diameter and 0.4 mm in height. 
Considering dimensional tolerances, a cylindrical mold with 9.0 mm outer diameter, 8.6 
mm inner diameter, and 1.5 mm height (Figure 5A) was created as a scaffold to contain 
the fluid VIC-laden pre-polymer mixture. Pluronic gel (Pluronic F-127; BioBots, 
Philadelphia, PA, USA), a sacrificial biocompatible material that dissolves in warm PBS, 
was utilized to construct the mold. Because of the low viscosity of the pre-polymer 
mixture, the hydrogel disc was designed as 8.0 mm in diameter and 0.1 mm in height 
(Figure 5B). Both designs were saved and downloaded as STL (STereoLithography) files, 
which were then imported to Repetier-Host (version 1.6.1; Hot-World GmbH & Co. KG, 
Willich, Germany) where the 3D designs were sliced into 100 µm a layer (Figure 5C). 
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The cylindrical mold and the disc were assigned to Extruder 1 and Extruder 2, 
respectively. The Slic3r settings for each extruder are provided in Table 1. Each design 
was sliced and saved as a separate file and subsequently customized into one single G-
code file. For printing, the G-code file was uploaded into the BioBots 3D bioprinter 
software. 
 
Table 1. Slic3r Settings for Bioprinter Extruders 
 
 
 
Figure 5. Generating 3D bioprinting blueprints on Tinkercad and Repetier-Host. 
(A) Design shows the cylindrical mold that encapsulates the hydrogel disc (9.0 mm outer 
diameter x 8.6 mm inner diameter x 1.5 mm height). (B) Design shows the hydrogel disc 
(8.0 mm diameter x 0.1 mm height). (C) Both 3D designs were sliced into 100 µm a layer 
by Slic3r on Repetier-Host. 
 
Bioprinting of Human VIC-Laden 3D Hydrogels 
A pressure-driven bioprinter (BioBot1; BioBots) equipped with two heated 
extruders assembled in motor-driven X-Y-Z stages was used to fabricate bioprinted 
 
Speed (mm/s) Layer height (mm) Infill Nozzle diameter (mm) 
Extruder 1 4 0.1 95% 0.15 
Extruder 2 5 0.1 60% 0.15 
A B C 
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human-VIC laden 3D hydrogels. The bioprinter was installed in a tissue culture room 
under the hood to ensure sterile conditions. 
Pluronic gel was stored at 4 °C as a liquid consistency. Prior to experimental use, 
pluronic gel was loaded into a 10 mL Luer-Lok syringe and left at room temperature for 
about 20 minutes until a gel-like consistency was reached. The syringe was capped with a 
disposable 27-gauge dispense nozzle (0.25” NT Premium Series; Jensen Global Inc., 
Santa Barbara, CA, USA), and air bubbles were removed. Then the syringe was loaded 
into the canister of Extruder 1. The 10 mL Luer-Lok syringe containing either VIC-laden 
or cell-free pre-polymer mixture was capped with a disposable 27-gauge Micron-S 
Precision dispense nozzle (Fisnar 5901007; Ellsworth Adhesives, Wilmington, MA, USA) 
and loaded into the canister of Extruder 2. All dispense nozzles were sterilized before use. 
Next, extruder pressures were calibrated corresponding to the consistency of the 
bioink materials used. For Extruder 1, pressure was adjusted to 43 psi until the pluronic 
gel was slowly extruded as a continuous filament. For Extruder 2, pressure was lowered 
to 0.6 psi given the low viscosity of the pre-polymer mixture. 
Calibration of the extruder nozzles to the plate was performed next. Petri dishes 
(Fisherbrand; Thermo Fisher Scientific, Waltham, MA, USA) were used as the printing 
surface. Extruder 1 was lowered into the plate until the nozzle was able to dispense a 
uniform dot on the surface without creating a dangling line. After Extruder 1 was 
calibrated, Extruder 2 was lowered into the plate directly on top of the dot created by 
Extruder 1 for calibration. In this step, the printing surface was raised to the highest 
position (in Y-axis) in order to calibrate Extruder 2 successfully. Extruder pressures were 
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not modified after nozzle positions were calibrated. A new petri dish was used for each 
print; hence nozzle calibrations were repeated prior to each print. 
Once all calibrations were finished, a G-code file was uploaded to the BioBots 
software, and printing proceeded. The printed construct consisted of a gel-like mold 
encapsulating fluid-like pre-polymer mixture as depicted in Figure 6. The construct was 
subsequently photocrosslinked using a built-in UV light (405 nm) underneath Extruder 2 
at an intensity of 16 mW/cm2 for 90 seconds. The resulting hydrogel discs were then 
immersed in warm PBS for 5 minutes and protected from light. Lastly, the hydrogel discs 
were carefully transferred to and cultured in 24-well plates containing growth medium for 
48 hours. Half of the hydrogel discs were placed into an osteogenic environment for 21 
days. Media were replenished 3 times a week. 
For the short-term pilot study (48 hours), a total of four VIC-laden hydrogels were 
printed and cultured in growth media for 48 hours prior to assessment. Two hydrogels 
were designated for proliferation and apoptosis assessments. For each long-term 
experiment (21 days), a total of fourteen VIC-laden hydrogels were printed and divided 
into two culturing conditions. Three hydrogels from each culturing condition were used 
for proliferation assessment, and four were used for apoptosis assessment (including one 
for positive control). Two cell-free hydrogels were also printed in each long-term 
experiment as negative controls (with VICs omitted). 
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Figure 6. Step-by-step progression of bioprinting hydrogel discs. (A) Cylindrical 
mold bioprinted with pluronic gel. (B) Cylindrical mold filled with hydrogel pre-polymer 
mixture. (C) bioprinted construct under UV light. (D) 3D construct after UV exposure. 
(E) Hydrogel disc in growth medium. 
 
Calcification Promotion 
Induction of calcification in VIC-laden hydrogels was carried out by culturing 
VIC-laden hydrogels for 21 days in osteogenic medium consisting of DMEM with 5% 
fetal calf serum, 10 mM b-glycerophosphate, 10 nM dexamethasone, and 50 µg/mL 
ascorbic acid. This recipe was modified from previous studies32,50 to optimize 
osteogenesis in human VICs. b-Glycerophosphate is a tissue nonspecific alkaline 
phosphatase (TNAP) substrate which activates the conversion of phosphate sources into 
free phosphate, promoting the mineralization process. 
 
Cell Proliferation and Apoptosis 
Cell proliferation was assessed by the Click-iT EdU Alexa Fluor 488 Imaging Kit 
(Thermo Fisher Scientific). Cell-laden hydrogels were incubated with 10 µM EdU, a 
reagent that binds to cell nuclei when cells are in the S-phase of the cell cycle, for 12 
A B C D E 
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hours prior to fixing. Samples were then fixed, permeabilized, and stained according to 
the manufacturer’s instructions. Cell nuclei were counterstained with DAPI (4ʹ′ ,6-
diamidino-2-phenylindole). Samples were either imaged immediately or stored in PBS at 
4 °C until use. 
Apoptosis was determined by Click-iT TUNEL (terminal deoxynucleotidyl 
transferase-dUTP nick end labeling, where dUTP is 2ʹ′ -deoxyuridine 5ʹ′ -triphosphate) 
Alexa Fluor 488 Imaging Assay (Thermo Fisher Scientific). The same cell-laden 
hydrogels used for calcification detection with Osteosense (see Detection of 
Microcalcifications section) were also used for apoptosis labeling. Cell-laden hydrogels 
were fixed, permeabilized, and stained according to the manufacturer’s instructions. 
Positive controls were prepared by incubating cell-laden hydrogels in DNase I 
(deoxyribonuclease I; included in the kit) for 30 minutes prior to staining. Cell nuclei 
were counterstained with DAPI. Samples were either imaged immediately or stored in 
PBS at 4 °C until use. 
Samples were imaged using an A1 confocal microscope (Nikon Instruments Inc., 
Melville, NY, USA), and Z-stacks were obtained using NIS-Elements Confocal software 
(Nikon Instruments Inc.). The Z-stacks were uploaded into ImageJ software (National 
Institutes of Health, Bethesda, MD, USA) where they were compressed into maximum 
intensity projection images and quantified. Data were depicted as percentage of positively 
stained cells. 
 
	  22 
Detection of Microcalcifications 
The imaging of microcalcifications in the VIC-laden 3D hydrogels was 
accomplished by utilizing Osteosense 680EX (Perkin Elmer, Boston, MA, USA), a 
bisphosphonate-based fluorescent calcium tracer that binds to hydroxyapatite in actively 
mineralized regions. Osteosense reagent was added to either the control medium or the 
osteogenic medium culturing VIC-laden 3D hydrogels at 1:200 dilution and incubated at 
37 °C and 5% CO2 for 12 hours. Following incubation, VIC-laden 3D hydrogels were 
washed with PBS twice. These same hydrogels were subsequently fixed and stained with 
the TUNEL assay for detecting apoptosis. Osteosense signals were visualized using an 
A1 confocal microscope at 650 nm excitation and 680 nm emission. Z-stacks were 
obtained and uploaded into ImageJ software, compressed into maximum intensity 
projection images, and quantified (see Cell Proliferation and Apoptosis section). 
 
Statistical Analysis 
Statistical analysis was performed using GraphPad Prism 7 (GraphPad Software, 
Inc., La Jolla, CA, USA). Data were presented as the mean ± standard error of the mean 
(SEM). A two-tailed, unpaired t-test was used to evaluate statistical differences between 
two groups. Comparisons of values among multiple groups were carried out by one-way 
analysis of variance (ANOVA) followed by Tukey’s multiple comparisons test. A value 
of P < 0.05 was considered significant. 
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RESULTS 
 
Short-Term Pilot Study 
Proliferation and apoptosis of human VICs in 3D-bioprinted hydrogels were first 
evaluated in a short-term pilot study using EdU and TUNEL assays, respectively. The 
purpose of this pilot study was to confirm that human VICs could survive in a 3D 
hydrogel system. VIC-laden hydrogels were bioprinted and cultured in growth media for 
48 hours prior to evaluation. DAPI, which counterstains nuclei, was used to visualize the 
overall distribution and number of encapsulated cells. Figure 7 shows representative 
maximum intensity projection images compressed from Z-stacks obtained by confocal 
microscopy. Quantifications of percent proliferation (number of proliferating cells/total 
number of cells) and percent apoptosis (number of apoptotic cells/total number of cells) 
are illustrated in Table 2. Overall, cell proliferation in the hydrogels after 48 hours of 
culture was 5.19% (n = 2), and cell apoptosis was 28.4% (n = 2). Statistical analysis was 
not performed because of the insufficient number of replicates. 
 
Figure 7. Cell proliferation and apoptosis in 3D-bioprinted hydrogels after 48 hours 
of culture. Human VIC-laden hydrogels were cultured in growth media for 48 hours. 
Each panel is a representative maximum intensity projection image of bioprinted VIC-
laden hydrogels stained using either EdU or TUNEL assay. Scale bar: 200 µm. 
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 Table 2. Quantification of VIC Proliferation and Apoptosis in Pilot Study* 
 
 
 
 
 
 
 
 *Data are depicted as percent proliferating cells or percent apoptotic cells (n = 2). 
 
Proliferation and Apoptosis in 3D-Bioprinted Human VIC-Laden Hydrogels 
After the survival of VICs in a 3D hydrogel platform was verified, long-term 
experiments were subsequently conducted. VIC-laden hydrogels were cultured in either 
control media (CM) or osteogenic media (OM) for 21 days, after which cell proliferation 
and apoptosis were evaluated. Figure 8 depicts representative maximum intensity 
projection images compressed from Z-stacks obtained by confocal microscopy. 
Quantification analyses are illustrated in Figure 9. Cell proliferation in the hydrogels 
(Donor 1) at day 21 was 9.48 ± 6.58% (n = 3) and 8.97 ± 2.95% (n = 3) in CM and OM 
conditions, respectively. No significant difference (p = 0.946) was observed in the 
percent cell proliferation between these two groups. Similarly, no significant difference 
(p = 0.428) was seen in the percent apoptosis between CM (12.6 ± 5.71%; n = 3) and OM 
(20.6 ± 7.00%; n = 3) after 21 days of culture. The repeated experiment using VICs 
isolated from a second donor valve (Donor 2) revealed a similar trend in the percent 
proliferation (CM: 0.17 ± 0.10%; n = 3 vs. OM: 0.04 ± 0.04%; n = 3; p = 0.286) (Figure 
9E). The apoptosis assay could not be analyzed for the Donor 2 experiment because the 
positive control did not demonstrate reliable staining results because of technical issues. 
 
Hydrogel 1 Hydrogel 2 Mean 
Proliferation 6.58% 3.79% 5.19% 
Apoptosis 34.50% 22.28% 28.39% 
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Therefore, no quantification data on cell apoptosis were provided for the Donor 2 
experiment. 
A handmade trial using human VICs (Donor 3) was conducted for comparison. 
Similar to the bioprinted hydrogel experiments, handmade VIC-laden hydrogels were 
cultured in either CM or OM for 21 days. Because this trial did not have a sufficient 
number of replicates, statistical analysis was not performed. After 21 days of culture, 
percent cell proliferation in the control (61.2%%; n = 2) and in the osteogenic (88.7%; n 
= 2) groups remained similar (Figure 9E). However, quantification on cell apoptosis 
could not be performed as a result of elevated nonspecific background staining (Figure 
10). Therefore, no quantification data on cell apoptosis were provided for the handmade 
trial. 
Figure 8. Proliferation, apoptosis, and calcification in bioprinted human VIC-laden 
hydrogels after 21 days of culture. Each panel is a representative maximum intensity 
projection confocal image (n = 3) from hydrogels encapsulating Donor 1 VICs. Top 
panels depict hydrogels cultured in control media (CM). Bottom panels depict hydrogels 
cultured in osteogenic media (OM). Apoptosis in TUNEL positive controls was induced 
by DNase I. Scale bar: 200 µm. 
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Figure 9. Quantifications of VIC proliferation, apoptosis, and microcalcification in 
long-term studies. Data are depicted as mean ± SEM. *p < 0.05, ****p < 0.0001, ns = 
not significant. (A) Microcalcification in bioprinted hydrogels encapsulating Donor 1 
VICs at day 21. (B) Cell proliferation in bioprinted hydrogels encapsulating Donor 1 
VICs at day 21. (C) Cell apoptosis in bioprinted hydrogels encapsulating Donor 1 VICs 
at day 21. (D) Comparison of microcalcification between bioprinted hydrogels and 
handmade hydrogels at day 21. (E) Comparison of cell proliferation between bioprinted 
hydrogels and handmade hydrogels at day 21. 
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Figure 10. Comparison of TUNEL and Osteosense staining between bioprinted and 
handmade hydrogels. Each panel is a representative maximum intensity projection 
confocal image. (A) Bioprinted hydrogels show less nonspecific background staining 
than handmade hydrogels. (B) Bioprinted hydrogels demonstrate stronger Osteosense 
signals than handmade hydrogels. CM = control media; OM = osteogenic media. Scale 
bar: 200 µm. 
 
Microcalcification in 3D-Bioprinted Human VIC-Laden Hydrogels 
Microcalcification formation in bioprinted hydrogels was evaluated after 21 days 
of osteogenic stimulation. Under macroscopic observation (Figure 11), there was no 
visible difference between the control group and the osteogenic group on day 1. 
However, after 21 days of exposure to osteogenic conditions, white solid deposits 
accumulated only in the osteogenic group, suggesting mineral deposition in the culturing 
well. No contamination was observed in any culturing wells after 21 days. With further 
inspection under light microscopy (Figure 12), VIC-laden hydrogels cultured in OM were 
darker overall and exhibited more abundant and larger dark spots compared with similar 
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hydrogels cultured in CM. Dark spots were a typical appearance of osteogenic-induced 
microcalcification formations under light microscopy.  
 Microcalcification in hydrogels at day 21 was labeled using Osteosense 680EX 
fluorescent calcium tracer and visualized under confocal microscopy as shown in Figure 
8. A volume view provided in Figure 13 depicts calcification formation throughout the 
entire hydrogel composite. Quantitative analysis (Figure 9A) revealed a significantly 
higher level of calcification (p < 0.0001) in VIC-laden hydrogels cultured in OM (1628 ± 
40.4 nodules) compared with similar hydrogels cultured in CM (53 ± 25.5 nodules). In 
addition, a repeated experiment using Donor 2 revealed the same trend, with a 
significantly increased level of calcification in OM conditions (CM: 527 ± 225.5 nodules 
vs. OM: 1556 ± 153.7 nodules; p = 0.019) (Figure 9D). Cell-free hydrogels cultured in 
either condition did not show any positive signals after staining with DAPI and 
Osteosense 680EX (Figure 8). 
 In handmade human VIC-laden 3D hydrogels, the level of calcification in the 
hydrogels cultured in OM (1732 nodules; n = 2) was higher compared with the hydrogels 
cultured in CM (725 nodules; n = 2). This result was similar to what was observed in the 
bioprinted models (Figure 9D). Also, the level of calcification in the OM conditions of 
handmade human VIC-laden 3D hydrogels (1732 nodules; n = 2) was comparable with 
the level of calcification in the OM conditions of bioprinted hydrogels (Donor 1: 1628 ± 
40.4 nodules; Donor 2: 1556 ± 153.7 nodules). However, bioprinted hydrogels cultured in 
CM (Donor 1: 53 ± 25.5 nodules; Donor 2: 527 ± 225.5 nodules) had relatively lower 
	  29 
levels of calcification compared with the handmade hydrogels cultured in CM (725 
nodules; n = 2). 
 
 
Figure 11. Macroscopic view of culturing wells containing VIC-laden hydrogel discs. 
Top panels depict bioprinted VIC-laden hydrogel discs in the culturing wells containing 
control media (CM) on day 1 and day 21. Bottom panels depict bioprinted VIC-laden 
hydrogel discs in the culturing wells containing osteogenic media (OM) on day 1 and day 
21. White solid deposits, indicated by yellow arrows in the bottom right panel, were 
observed only in the culturing wells of hydrogel discs in OM after 21 days of culture. No 
gross difference in the macroscopic appearance of hydrogels was seen between the two 
culturing conditions. 
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Figure 12. Microscopic view of VIC-laden hydrogels after 21 days of culture. For 
bioprinted VIC-laden hydrogels, larger dark spots indicating microcalcifications were 
more abundant in the hydrogels cultured in osteogenic media (OM), as noted by red 
arrows, than in the hydrogels cultured in control media (CM). Hydrogels cultured in OM 
conditions appeared darker overall microscopically. Both images were taken under the 
same brightness. Magnification: 40X. 
 
Figure 13. Confocal image volume views. Volume views of the Z-stacks obtained from 
Donor 1 VIC-laden hydrogels after 21 days of culture in either CM (top) or OM (bottom). 
Cell nuclei, labeled in blue, were distributed throughout the entire hydrogel composites in 
both CM and OM culturing conditions. Microcalcification, labeled in red, also formed 
throughout the entire hydrogel composites in OM culturing conditions. CM = control 
media; OM = osteogenic media.   
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DISCUSSION 
 
Validation of the 3D-Bioprinted Hydrogel Platform 
 In this study, a functional monolayered 3D-bioprinted cell-laden hydrogel 
platform that simulates the microcalcification formation as seen in early CAVD was 
established. We demonstrated that, by introducing pro-osteogenic conditions mimicking 
the conditions in CAVD, human VICs encapsulated in the 3D-bioprinted hydrogels 
formed more microcalcification after 21 days of culture than under normal conditions. 
This tendency was consistent between experiments using two different VIC donors, 
suggesting that the results were not donor-dependent. Overall, these findings support 
previously reported results on porcine VIC-laden hydrogels31 composed of the same 
GelMA and HAMA concentrations as the 3D-bioprinted hydrogels used in this study. In 
a handmade porcine VIC-laden hydrogel platform, Hjortnaes et al.31 demonstrated that 
the encapsulated VICs maintained a quiescent phenotype in normal conditions 
resembling a healthy native valve environment. Their study further demonstrated that, 
upon osteogenic stimulation, encapsulated VICs underwent myofibroblast-like and 
eventually osteoblast-like differentiations, mimicking the pathological phenotype changes 
in early CAVD. Therefore, based on the identical experimental setups and similar results 
obtained between the handmade porcine model and the novel bioprinted human model, 
we have validated that our 3D-bioprinted version of the VIC-laden hydrogel platform is a 
comparable system that simulates events occurring in early CAVD. 
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Comparison Between Bioprinted Platform and Handmade Platform 
 In the present study, handmade cell-laden hydrogels using human VICs were also 
fabricated as a closer comparison with the bioprinted human VIC-laden hydrogels. In the 
control groups, either a similar or lower microcalcification level was observed in the 
bioprinted hydrogel platforms than in the handmade hydrogel platforms after 21 days of 
culture. Although this difference may be associated with donor-to-donor VIC variability, 
it is possible that the bioprinting technology may have improved the cell-matrix 
integration within the hydrogels, hence maintaining more VICs in the quiescent state 
without undergoing spontaneous differentiation. However, this comparison was not ideal 
because there were not enough replicates in the handmade groups for statistical analysis 
and because different VIC donors were compared. Therefore, repeated experiments using 
the same donors in both fabrication methods are necessary to make a stronger argument. 
  Next, as shown in Figure 10, handmade hydrogels had an elevated nonspecific 
background staining, making them unsuitable for quantitative TUNEL analysis and less 
reliable for Osteosense quantification. On the other hand, bioprinted hydrogels had more 
specific staining, allowing for improvements in quantitative assessment. As such, 
bioprinted hydrogels may provide a better means through which to quantitatively assess 
VIC calcification in a 3D culture platform. 
 Taken together, the results for the bioprinted VIC-laden hydrogel platforms 
demonstrated an advantage over the handmade hydrogel platforms. However, further 
investigations will be necessary to confirm the differences in the effect on cell 
environment exhibited between the two fabrication methods. 
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Mechanisms of Calcification 
 In addition, our findings in this study may extend the evidence that calcification 
occurs through a (1) cell-dependent, (2) apoptotic-independent, and (3) proliferation-
independent process. Calcification is characterized by the deposition of calcium 
phosphate minerals within the ECM of the tissue. Previous work revealed that 
inflammation-mediated calcification may be driven by two pathways.51 Pro-inflammatory 
stimuli may induce calcification through promotion of both cell apoptosis and osteogenic 
differentiation. Alternatively, osteogenic transition of VICs may induce the loading of 
active tissue nonspecific alkaline phosphatase (TNAP) into extracellular vesicles (EV) for 
phosphate trafficking and mineral deposition.42,52 In this study, an osteogenic protocol 
consisting of b-glycerophosphate, a TNAP substrate that activates the process of 
converting pyrophosphate into free phosphate to allow mineralization was used. After 21 
days of osteogenic stimulation, significantly increased microcalcification was observed in 
3D-bioprinted hydrogels encapsulating human VICs. In contrast, there was no 
microcalcification in cell-free hydrogels cultured in osteogenic conditions, suggesting 
that the formation of microcalcification was cell-dependent and not a simple nucleation 
of mineral sources from the media and/or cell-free hydrogel components.  
Next, the levels of microcalcification in relation to cell apoptosis between the 
Donor 1 control and osteogenic groups were compared. Although there was an increase 
in microcalcification in the Donor 1 osteogenic group (Figure 9A), this change did not 
correspond with an increase in cell apoptosis (Figure 9C). This suggests that, although 
cell apoptosis could be involved in the promotion of calcification, the major pathway was 
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generated through trafficking of TNAP by means of calcifying EV as described 
previously.52,53 For example, in the Goettsch et al. study, the loading of the calcification 
protein, TNAP, into EV was regulated by sortilin phosphorylation.52 As a result, our 
finding was consistent with current literature in support of calcification as a mainly 
apoptosis-independent pathway. 
Finally, the levels of microcalcification in relation to cell proliferation between 
control and osteogenic groups were compared. It was found that the percentage cell 
proliferation (Figure 9E) was not significantly changed in the osteogenic groups despite a 
significant increase in microcalcification (Figure 9D). This tendency was consistent 
across all donor groups in both fabrication methods. Therefore, our finding suggests that 
calcification formation acts through a proliferation-independent pathway. 
 
Challenges and Limitations of the Study 
 In this study, the primary VICs were isolated from diseased valves excised from 
end-stage CAVD patients. As such, these VICs were “preconditioned,” and therefore 
certain extents of microcalcification were observed in the control groups. Despite this 
issue, the increase in microcalcification in the osteogenic groups was still significant. If 
VICs from healthy donors could be used, more consistent data across the control groups 
may be observed, and the significant difference between control and osteogenic groups 
may be enhanced. 
 Also, the large amount of primary VICs required for each experiment posed a 
significant challenge, which limited the number of cell-laden hydrogels that could be 
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prepared for each experiment. As a result, only two technical replicates per group were 
constructed in the handmade trial and in the pilot study. Each VIC isolation from donor 
valves provided only a small fraction of the overall number of primary cells required for 
each experiment (10 million cells/mL of hydrogel pre-polymer mixture). Moreover, VICs 
have a slow proliferation rate, likely because they normally exist in a quiescent state and 
they were obtained from donors of old age (typical for CAVD). In order to reach the 
adequate amount of cells required for each experiment, VICs were initially expanded on 
the traditional 2D cell culture for up to 6 passages before being encapsulated in 3D 
constructs. Therefore, this process may have triggered spontaneous VIC differentiation to 
some extent, which may serve as another reason why microcalcification was observed in 
control groups. The slow growth of VICs may also provide an explanation for the low 
cell proliferation observed in the 3D constructs. 
 Another limitation of this study was the batch-to-batch variability of the hydrogel 
pre-polymers. A uniform degree of methacrylation was not achievable given the current 
synthesis protocol. Therefore, the length of UV-crosslinking time was adjusted for each 
new batch of pre-polymer in order to keep the hydrogel stiffness consistent. Identifying 
the ideal length of UV-crosslinking time, however, would be difficult without 
incorporating additional mechanical characterization of the hydrogels. 
 Lastly, the temperature-dependent viscosity of the hydrogels was the main 
challenge in this study. For bioprinting, hydrogels had to be maintained at the right 
viscosity. When the hydrogels were too fluid, they would leak through the nozzles even 
on the lowest extrusion pressure setting. On the contrary, if the hydrogels were too 
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viscous, they would clog the extruder nozzles. This difficulty was compounded by the 
fact that the extruder nozzles were not heated, a problem that increased the likelihood of 
clogging. Therefore, external add-ons for the bioprinter featuring nozzle heating and 
perhaps smaller increments of pressure control should be considered in future studies if 
the same bioprinter is used. 
 
Future Studies  
 Given the limitations discussed in the preceding section, future work should aim 
to address these issues. Furthermore, as cell proliferation and apoptosis do not directly 
assess cell viability, other assessment methods, such as the Live/Dead viability assay, 
should be added. Also, the various assessments, including calcification, cell survival, and 
cell apoptosis, should be conducted at several time points to study the changes over time. 
Additionally, because extracellular vesicle trafficking plays a significant role in 
calcification formation, further investigations into this mechanism on a 3D platform 
should be considered. 
 For long-term goals, other types of hydrogel materials should be investigated as 
potential bioinks for constructing the additional layers of the 3D disease model. Isolation 
of VECs from donor valves and VEC culturing protocols should also be optimized in 
preparation for VIC-VEC co-culturing in the 3D hydrogel platform. 
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Future Applications 
 Establishing an in vitro disease model with human cells to mimic the native tissue 
environment will open doors to many advances in the field. Scientifically, this model will 
provide a platform to elucidate CAVD mechanisms in an environment similar to the 
native valve. Clinically, this platform will be used for identifying, screening, and testing 
novel therapeutic targets that may provide the means to treat patients with CAVD. And 
ultimately, this platform may potentially be the first step toward building a 3D-bioprinted 
implantable tissue-engineered heart valve. 
 
Conclusion 
 With the use of bioprinting technology, a functional monolayered cell-laden 
hydrogel platform was established as a first step toward building an in vitro multilayered 
disease model for studying the mechanisms leading to calcification in CAVD. Confocal 
analysis revealed increased formation of microcalcification in the 3D-bioprinted VIC-
laden hydrogels cultured in an osteogenic environment for 21 days. In comparison with 
handmade hydrogels, the bioprinted hydrogels were considered a better culturing 
platform because they exhibited a lower calcification level in control groups and less 
nonspecific background staining for more reliable assessments. This study further 
provided evidence in support of a cell-mediated, apoptotic-independent, and 
proliferation-independent calcification pathway. 
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